A股上半年行情收官。东方财富Choice数据显示，今年上半年，剔除退市股和ST股，A股479只生物医药股中，313只个股跑赢大盘，占比超过65%。其中， 舒泰神（300204）股价涨幅最猛，涨超4倍。智飞生物成为最熊股，上半年股价累计下跌25.51%。此外，爱博医疗、健帆生物等股价跌幅同样在20%以上。 不过，部分股价大涨的个股并无业绩支撑，诸如上半年股价实现翻倍的热景生物，2024年净利由盈转亏；而"涨幅王"舒泰神，归属净利润已连亏五年。 | | | | | 归属于母公司股东 ... | 归属母公司股东的 ... | 所属行业名称 行 标准 电方行业(2. | 区间涨跌幅 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | 证券代码 | 证券名称 | ممية | [报告期]去年年报 [报告类型]合并报表 单位 亿元 | [报告期]去年年报 [单位]% | [行 类别 3级 國正日期1号新(2025- | | [起始交易日期]本年初 (截止交易日期1202 ... 复权方式信复权 | | | | | | | | | [单位]% ...

"生物创新智造中心项目可以有效解决公司在生物医药领域的临床样品制备及生产等产业化发展需 求。"华东医药相关负责人表示。 该项目的落地，也将撬动更多生物医药产业核心要素集聚，进一步深化和强化生物医药创新研发生 态圈和技术平台建设，助力拱墅区招引成熟项目、企业落地，带动更多成果转化与产值产出，打造具有 全球影响力的生物医药产业转化创新高地。未来拱墅还将重点推进抗体偶联产业化、合成生物学产业化 等平台建设，目标到2035年，再造一个"中美华东"。 华东医药生物创新智造中心项目效果图 在当下的经济格局中，高新技术产业投资已成为衡量区域经济发展潜力与创新活力的关键指标。作 为杭州主城区产业转型的先锋，拱墅区正通过一系列有力举措，推动高新技术产业投资迅猛增长，为区 域经济高质量发展注入澎湃动力。今年1-5月，该区高新技术产业投资同比增长49%，增速位居全市第 一。其中，华东医药生物创新智造中心、杭叉云瑞、罗莱智慧照明总部等一批优质产业项目相继落地， 蓝奥科技园、新中大科技园、高信科创、货拉拉智汇云谷等一批重点产业项目加快进程，产业提质加速 向新。 镜头：投资20亿元，再造一个"中美华东" 夏至将近，拱墅区半山街道临一街上 ...

| 万门 月強 史多同郎 ▲ 5日 ▼ 5分钟 15分钟 30分钟 60分钟 日33 )리Ξ조 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 舒泰神 (日线,不复权) ⑦ ◎ MA MA5:34.72 ↑ MA10:33.07 ↑ MA20:25.21 ↑ MA30:20.37 ↑ MA60:14.31 ↑ MA120:10.83 ↑ MA250:18.82 ↑ t 兼 1 兼 兼 | 兼 | ★ ★ | 兼 | * * | 兼 | 兼 | | | 兼 | | | | | | | 1 | | 7 VOL (5, 10) VOLUME : 40.507万 ↓ MAVOL1:49.814万 ↓ MAVOL2:54.565万 | | | | | | | | | ่อนที่ 2008 ครั้ง 2017 ครั้ง 2017 ครั้ง 2017 ครั้ง 200 ครออง 2000 ครอบครอง 2000 คน 2017 คน 2017 คน 14 เมื่อ 10 พ. 6 เ ? VOL(5,10) VOLUM ...

Core Viewpoint - The company has granted Pfizer exclusive rights to develop, produce, and commercialize a dual-targeting antibody product aimed at PD-1 and VEGF, which is expected to enhance anti-tumor effects while reducing potential side effects [1][3]. Group 1: Licensing Agreement - Sanofi Health has granted Pfizer exclusive rights for the development and commercialization of the 707 project in regions outside mainland China [1]. - The licensing agreement involves a distribution of rights based on prior R&D investments and asset ownership, with Sanofi Health receiving 30% and Shenyang Sanofi receiving 70% [2]. Group 2: Clinical Development - The efficacy and safety of the PD-1/L1 antibody combined with VEGF antibody have been validated in clinical trials for various tumors, including renal cell carcinoma and hepatocellular carcinoma [3]. - The product has multiple ongoing clinical trials, with a single-agent treatment for PD-L1 positive non-small cell lung cancer having received approval for Phase III, while combination therapies for non-small cell lung cancer, metastatic colorectal cancer, and advanced gynecological tumors are in Phase II [3]. Group 3: Financial Projections - Following the significant licensing agreement and the anticipated approval of new products, the company has adjusted its revenue forecasts for 2025-2027 to 40.2 billion, 22.4 billion, and 26.3 billion yuan, reflecting a year-on-year growth of 236.4%, -44.1%, and 17.4% respectively [4]. - The projected net profits for the same period are 28.5 billion, 11.2 billion, and 13.9 billion yuan, with year-on-year growth of 305.0%, -60.6%, and 23.4% respectively [4]. - Earnings per share (EPS) are expected to be 4.63, 1.82, and 2.25 yuan, with corresponding price-to-earnings (PE) ratios of 12, 30, and 24 times based on the closing price of 54 yuan per share on May 28, 2025 [4].

Core Points - The company is holding a second extraordinary general meeting of shareholders in June 2025 to discuss several key proposals [1][8] - The meeting will ensure the rights of shareholders and maintain order, with specific rules for attendance and participation [2][4] Proposal Summaries - Proposal 1: The company plans to sign a licensing agreement with its affiliates and Pfizer Inc. for a dual-targeting antibody product, granting exclusive rights for development and commercialization outside mainland China [4][6] - Proposal 2: A supplementary agreement regarding the distribution of payments from Pfizer under the licensing agreement will be established, with a proposed distribution ratio of 30% for the company and 70% for its affiliate [6][7] - Proposal 3: The company intends to temporarily use surplus funds of 66.6282 million yuan from various projects to supplement working capital and adjust the investment amounts for specific projects, reducing one project’s funding from 400 million yuan to 320 million yuan and increasing another from 610 million yuan to 690 million yuan [7][8]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 5月23日，A股午后全线跳水，创业板指、北证50指数等跌超1%；富时中国A50指数期货盘中直线跳 水；港股亦回落，恒生科技指数翻绿。 具体来看，两市股指盘中震荡回落，尾盘加速下探，创业板指等跌逾1%。截至收盘，沪指跌0.94%报 3348.37点，深证成指跌0.85%报10132.41点，创业板指跌1.18%，科创50、北证50指数均跌超1%，沪深 北三市合计成交11828亿元，较此前一日增加429亿元。 | મ્દ્રિક | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 3348.37 c | -31.82 | -0.94% | | 399001 | 深证成指 | 10132.41 c | -87.21 | -0.85% | | 899050 | THESO | 1370.04 c | -18.79 | -1.35% | | 881001 | 万得全A | 5075.37 c | -47.28 | -0.92% | | 000688 | ...

5月23日，A股午后全线跳水，创业板指、北证50指数等跌超1%；富时中国A50指数期货盘中直线跳水；港股亦回落，恒生科技指数翻绿。 具体来看，两市股指盘中震荡回落，尾盘加速下探，创业板指等跌逾1%。截至收盘，沪指跌0.94%报3348.37点，深证成指跌0.85%报10132.41点，创业板指跌 1.18%，科创50、北证50指数均跌超1%，沪深北三市合计成交11828亿元，较此前一日增加429亿元。 | HSRS | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 3348.37 c | -31.82 | -0.94% | | 399001 | 深证成指 | 10132.41 c | -87.21 | -0.85% | | 899050 | 北证50 | 1370.04 c | -18.79 | -1.35% | | 881001 | 万得全A | 5075.37 c | -47.28 | -0.92% | | 000688 | 科创20 | 980.58 c | -10.13 | -1.02% | | 39900 ...

Group 1 - The stock of Sanofi Guojian (688336) experienced a significant drop of over 10% during trading on the 23rd, following a continuous rise of 100% over the previous four trading days [1] - The company issued a risk warning on May 22, indicating the potential for irrational speculation and a market correction due to the substantial increase in stock price [1] - The trading volume exceeded 530 million yuan, reflecting heightened market activity [1] Group 2 - The company, along with its affiliates, granted Pfizer Inc. exclusive rights for the development, production, and commercialization of a dual-targeting antibody product (Project 707) outside of mainland China [2] - The revenue sharing from this licensing agreement is set at 30% for Sanofi Guojian and 70% for Shenyang Sanofi, based on prior R&D investments and asset ownership [2] - The agreement requires approval from the company's shareholders and antitrust regulatory bodies in the U.S. and other jurisdictions, introducing uncertainty regarding its effectiveness [2] Group 3 - The development, registration, and sale of the licensed product in the designated regions are subject to regulatory approvals, which are inherently uncertain due to the lengthy nature of new drug development [3] - Milestone payments tied to clinical and regulatory events are contingent upon the successful completion of specified conditions, adding another layer of uncertainty [3] - Sales milestone payments and royalties are dependent on market factors such as demand, competition, and sales channels, which may affect the actual revenue received by the licensing parties [3]

Group 1 - Daqian Ecology announced that shareholder Xinhua Publishing Group plans to reduce its stake by up to 4,071,600 shares, representing no more than 3% of the total share capital [2] - Vice President Wang Zheng'an intends to reduce his holdings by up to 410,798 shares, which is no more than 25% of his total holdings and approximately 0.3027% of the company's total share capital [2] - The reduction period is set from June 16, 2025, to September 15, 2025 [2] Group 2 - Sanofi's stock has experienced a significant increase, with a cumulative rise of over 30% in two consecutive trading days and over 100% in four consecutive trading days, indicating abnormal trading fluctuations [2] - The company has entered into a collaboration with Pfizer for the 707 project, which involves a dual-specific antibody product targeting PD-1 and VEGF, with uncertain sales milestone payments and royalties based on market conditions [2] - The actual receipt of sales milestone payments and royalties is subject to uncertainties related to drug demand, market competition, and sales channels [2] Group 3 - Xinhua Insurance announced a commitment to invest 10 billion yuan in the second phase of the Honghu Fund, which has a total fund size of 20 billion yuan [3] - The establishment of the fund is pending regulatory procedures, and the implementation timeline may vary [3] - Sany Heavy Industry has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange, with the application materials being subject to updates [3] Group 4 - Laisentongling's stock has seen a 33.17% increase over three consecutive trading days, with a turnover rate of 40.49%, indicating potential speculative trading [3] - The company confirmed that its main operations remain stable, with no significant changes in daily operations or major contracts signed recently [3] - The production costs and sales conditions are reported to be normal [3]

Core Viewpoint - The stock of Sangfor Technologies has experienced significant trading volatility, with a cumulative increase of over 100% in four consecutive trading days, raising concerns about irrational speculation and potential corrections [1][2][5]. Group 1: Stock Trading Volatility - The company's stock experienced abnormal trading fluctuations on May 21 and May 22, 2025, with a cumulative closing price deviation exceeding 30% [1][5]. - The stock's cumulative increase of over 100% from May 19 to May 22, 2025, qualifies as severe abnormal trading volatility according to Shanghai Stock Exchange regulations [1][5]. - As of May 22, 2025, the closing price was 56.69 CNY per share, with the company's rolling P/E ratio at 48.81, significantly higher than the industry average of 29.18 [2][7]. Group 2: Licensing Agreement - The company, along with its affiliates, granted Pfizer Inc. exclusive rights for the development, production, and commercialization of a dual-targeting antibody product outside mainland China [3]. - The revenue from the licensing agreement will be distributed based on prior R&D investments, with Sangfor receiving 30% and its affiliate 70% [3]. - The licensing agreement is subject to approval from the company's shareholders and relevant regulatory bodies, introducing uncertainty regarding its effectiveness [4][8]. Group 3: Company Operations and Risk Factors - The company confirmed that there are no undisclosed significant matters affecting its operations, and its business remains normal without major changes [2][6]. - The company emphasizes the uncertainty associated with new drug development, including clinical trials and regulatory approvals, which may impact the commercialization of the licensed product [4][9]. - The company urges investors to make rational decisions and be aware of the risks associated with stock price volatility and the licensing agreement [2][8].